Evidence map›Paper›PMID 33049996›Full record

ReviewInternational journal of molecular sciences2020

Recent Advances in

Fukiko Kitani-Morii, Yu-Ichi Noto

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Junctions in Jeopardy: the neuromuscular junction is a selective pathological target in Charcot-Marie-Tooth disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  2. Review
  3. Modeling of Charcot-Marie-Tooth disease in zebrafish.Frontiers in molecular neuroscience · 2025
    Review
  4. Expanding the Molecular Spectrum ofArchives of Iranian medicine · 2023
    Article
  5. Article
  6. Review
  7. Role ofInternational journal of molecular sciences · 2022
    Article
  8. Epigenetic Regulation of ALS and CMT: A Lesson fromInternational journal of molecular sciences · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fukiko Kitani-MoriiDepartment of Molecular Pathobiology of Brain Disease, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan.
Yu-Ichi NotoDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan.
Kyoto Prefectural University of Medicine · JP

Funding

Japan Agency for Medical Research and Development 17929553Ministry of Education, Culture, Sports, Science and Technology 19K16924
6 · The paper itself

Abstract

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited peripheral neuropathies. CMT patients typically show slowly progressive muscle weakness and sensory loss in a distal dominant pattern in childhood. The diagnosis of CMT is based on clinical symptoms, electrophysiological examinations, and genetic testing. Advances in genetic testing technology have revealed the genetic heterogeneity of CMT; more than 100 genes containing the disease causative mutations have been identified. Because a single genetic alteration in CMT leads to progressive neurodegeneration, studies of CMT patients and their respective models revealed the genotype-phenotype relationships of targeted genes. Conventionally, rodents and cell lines have often been used to study the pathogenesis of CMT. Recently,

Indexed as

Disease Models, AnimalAmino Acyl-tRNA SynthetasesAnimalsAxonal TransportCharcot-Marie-Tooth DiseaseChildDrosophila melanogasterHumansIntracellular MembranesL-Iditol 2-DehydrogenaseMitochondriaMutationPeripheral Nervous System DiseasesAmino Acyl-tRNA SynthetasesL-Iditol 2-DehydrogenaseCharcot-Marie-Tooth disease (CMT)Drosophila melanogasterhuman disease modelneurodegenerationperipheral neuropathy

Identifiers

PMID33049996
PMCPMC7582988
OpenAlexW3091842053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.